How have treatment patterns for patients with inflammatory bowel disease changed in Asian countries?
作者信息
Park Jihye
机构信息
Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.
出版信息
Intest Res. 2023 Jul;21(3):275-276. doi: 10.5217/ir.2023.00061. Epub 2023 Jul 27.
Abstract
摘要
相似文献
1
How have treatment patterns for patients with inflammatory bowel disease changed in Asian countries?亚洲国家炎症性肠病患者的治疗模式发生了怎样的变化？
Intest Res. 2023 Jul;21(3):275-276. doi: 10.5217/ir.2023.00061. Epub 2023 Jul 27.
2
Treatment of inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2(nd) Asian Organization of Crohn's and Colitis (AOCC) meeting in Seoul.亚洲炎症性肠病的治疗：在首尔举行的第二届亚洲克罗恩病和结肠炎组织（AOCC）会议上进行的一项基于网络的多国调查结果
Intest Res. 2016 Jul;14(3):231-9. doi: 10.5217/ir.2016.14.3.231. Epub 2016 Jun 27.
3
The emergence of inflammatory bowel disease in the Asian Pacific region.亚太地区炎症性肠病的出现。
Curr Opin Gastroenterol. 2005 Jul;21(4):408-13.
4
The epidemiology of inflammatory bowel disease in Asia and Asian immigrants to Western countries.亚洲及移居西方国家的亚洲移民炎症性肠病的流行病学
United European Gastroenterol J. 2022 Dec;10(10):1063-1076. doi: 10.1002/ueg2.12350. Epub 2022 Dec 8.
5
Differences in the public medical insurance systems for inflammatory bowel disease treatment in Asian countries.亚洲国家炎症性肠病治疗公共医疗保险体系的差异。
Intest Res. 2016 Jul;14(3):218-23. doi: 10.5217/ir.2016.14.3.218. Epub 2016 Jun 27.
6
Diagnosis of inflammatory bowel disease-Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn's and Colitis meeting.炎症性肠病的诊断——亚洲视角：第八届亚洲克罗恩病和结肠炎组织会议基于网络的多国调查结果
Intest Res. 2023 Jul;21(3):328-338. doi: 10.5217/ir.2023.00012. Epub 2023 Jul 27.
7
Diagnosis of inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2(nd) Asian Organization for Crohn's and Colitis (AOCC) meeting in Seoul.亚洲炎症性肠病的诊断：在首尔举行的第二届亚洲克罗恩病和结肠炎组织（AOCC）会议上进行的一项跨国网络调查结果
Intest Res. 2016 Jul;14(3):224-30. doi: 10.5217/ir.2016.14.3.224. Epub 2016 Jun 27.
8
Treatment of inflammatory bowel disease-Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn's and Colitis meeting.炎症性肠病的治疗——亚洲视角：第八届亚洲克罗恩病和结肠炎组织会议上一项基于网络的多国调查结果
Intest Res. 2023 Jul;21(3):339-352. doi: 10.5217/ir.2022.00135. Epub 2023 Jul 27.
9
The Impact of Inflammatory Bowel Disease in Canada 2018: Epidemiology.《2018年炎症性肠病在加拿大的影响：流行病学》
J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S6-S16. doi: 10.1093/jcag/gwy054. Epub 2018 Nov 2.
10
Prevention of Infectious Diseases due to Immunosuppression and Vaccinations in Asian Patients with Inflammatory Bowel Disease.亚洲炎症性肠病患者免疫抑制及疫苗接种导致的传染病预防
Inflamm Intest Dis. 2018 Nov;3(1):1-10. doi: 10.1159/000489643. Epub 2018 Jul 17.
本文引用的文献
1
Treatment of inflammatory bowel disease-Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn's and Colitis meeting.炎症性肠病的治疗——亚洲视角：第八届亚洲克罗恩病和结肠炎组织会议上一项基于网络的多国调查结果
Intest Res. 2023 Jul;21(3):339-352. doi: 10.5217/ir.2022.00135. Epub 2023 Jul 27.
2
The global, regional, and national burden of inflammatory bowel diseases, 1990-2019: A systematic analysis for the global burden of disease study 2019.1990 - 2019年全球、区域和国家炎症性肠病负担：全球疾病负担研究2019的系统分析
Dig Liver Dis. 2023 Oct;55(10):1352-1359. doi: 10.1016/j.dld.2023.04.003. Epub 2023 May 2.
3
Korean clinical practice guidelines on biologics for moderate to severe Crohn's disease.韩国中重度克罗恩病生物制剂临床实践指南。
Intest Res. 2023 Jan;21(1):43-60. doi: 10.5217/ir.2022.00029. Epub 2022 Oct 18.
4
Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis.韩国中重度溃疡性结肠炎生物制剂和小分子药物临床实践指南
Intest Res. 2023 Jan;21(1):61-87. doi: 10.5217/ir.2022.00007. Epub 2022 May 31.
5
Natural history of inflammatory bowel disease: a comparison between the East and the West.炎症性肠病的自然史：东西方比较
Intest Res. 2022 Oct;20(4):418-430. doi: 10.5217/ir.2021.00104. Epub 2021 Dec 2.
6
Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents.系统评价：生物制剂导致炎症性肠病的疾病社会成本增加，并因各大洲而异。
Aliment Pharmacol Ther. 2021 Aug;54(3):234-248. doi: 10.1111/apt.16445. Epub 2021 Jun 11.
7
Longitudinal Trends in the Direct Costs and Health Care Utilization Ascribable to Inflammatory Bowel Disease in the Biologic Era: Results From a Canadian Population-Based Analysis.生物制剂时代炎症性肠病的直接成本和医疗保健利用的纵向趋势：来自加拿大基于人群的分析结果。
Am J Gastroenterol. 2020 Jan;115(1):128-137. doi: 10.14309/ajg.0000000000000503.
8
Market share and costs of biologic therapies for inflammatory bowel disease in the USA.美国炎症性肠病生物治疗药物的市场份额和成本。
Aliment Pharmacol Ther. 2018 Feb;47(3):364-370. doi: 10.1111/apt.14430. Epub 2017 Nov 22.
9
Treatment of inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2(nd) Asian Organization of Crohn's and Colitis (AOCC) meeting in Seoul.亚洲炎症性肠病的治疗：在首尔举行的第二届亚洲克罗恩病和结肠炎组织（AOCC）会议上进行的一项基于网络的多国调查结果
Intest Res. 2016 Jul;14(3):231-9. doi: 10.5217/ir.2016.14.3.231. Epub 2016 Jun 27.
Zotero 插件